Total Valuation
Valeo Pharma has a market cap or net worth of $3.16M. The enterprise value is $71.50.
Market Cap$3.16M
Enterprise Value$71.50
Share Statistics
Valeo Pharma has 98,675,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding98,675,430
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Valeo Pharma’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is -67.29%.
Return on Equity (ROE)0.69
Return on Assets (ROA)-0.67
Return on Invested Capital (ROIC)-67.29%
Return on Capital Employed (ROCE)-0.82
Revenue Per Employee770.14K
Profits Per Employee-397.26K
Employee Count70
Asset Turnover1.31
Inventory Turnover3.99
Valuation Ratios
The current PE Ratio of Valeo Pharma is ―. Valeo Pharma’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value-0.31
Price to FCF0.00
Price to Operating Cash Flow>-0.01
PEG Ratio―
Income Statement
In the last 12 months, Valeo Pharma had revenue of 53.91M and earned -27.81M in profits. Earnings per share was -0.32.
Revenue53.91M
Gross Profit13.08M
Operating Income-17.23M
Pretax Income-27.81M
Net Income-27.81M
EBITDA-11.39M
Earnings Per Share (EPS)-0.32
Cash Flow
In the last 12 months, operating cash flow was -4.28M and capital expenditures -5.12M, giving a free cash flow of -9.40M billion.
Operating Cash Flow-4.28M
Free Cash Flow-9.40M
Free Cash Flow per Share-0.10
Dividends & Yields
Valeo Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.01
52-Week Price Change-8.00%
50-Day Moving Average0.05
200-Day Moving Average―
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
Valeo Pharma upcoming earnings date is Sep 10, 2025, TBA (Confirmed).
Last Earnings DateJun 17, 2025
Next Earnings DateSep 10, 2025
Ex-Dividend Date―
Financial Position
Valeo Pharma as a current ratio of 1.25, with Debt / Equity ratio of -161.56%
Current Ratio1.25
Quick Ratio0.74
Debt to Market Cap5.09
Net Debt to EBITDA-5.06
Interest Coverage Ratio-1.25
Taxes
In the past 12 months, Valeo Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Valeo Pharma EV to EBITDA ratio is -6.16, with an EV/FCF ratio of -3.30.
EV to Sales1.30
EV to EBITDA-6.16
EV to Free Cash Flow-3.30
EV to Operating Cash Flow-4.47
Balance Sheet
Valeo Pharma has $7.13M in cash and marketable securities with $1.00M in debt, giving a net cash position of -$62.96M billion.
Cash & Marketable Securities$7.13M
Total Debt$1.00M
Net Cash-$62.96M
Net Cash Per Share-$0.64
Tangible Book Value Per Share-$0.60
Margins
Gross margin is 24.26%, with operating margin of -31.96%, and net profit margin of -51.58%.
Gross Margin24.26%
Operating Margin-31.96%
Pretax Margin-51.58%
Net Profit Margin-51.58%
EBITDA Margin-21.13%
EBIT Margin-26.00%
Analyst Forecast
The average price target for Valeo Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―